The discovery of gut sweet taste receptors has led to speculations that non-nutritive sweeteners, including sucralose, may affect glucose control. A double-blind, parallel, randomized clinical trial, reported here and previously submitted to regulatory agencies, helps to clarify the role of sucralose in this regard. This was primarily an out-patient study, with 4-week screening, 12-week test, and 4-week follow-up phases. Normoglycemic male volunteers (47) consumed~333.3 mg encapsulated sucralose or placebo 3x/day at mealtimes. HbA1c, fasting glucose, insulin, and C-peptide were measured weekly. OGTTs were conducted in-clinic overnight, following overnight fasting twice during screening phase, twice during test phase, and once at follow-up. Throughout the study, glucose, insulin, C-peptide and HbA1c levels were within normal range. No statistically significant differences between sucralose and placebo groups in change from baseline for fasting glucose, insulin, C-peptide and HbA1c, no clinically meaningful differences in time to peak levels or return towards basal levels in OGTTs, and no treatment group differences in mean glucose, insulin, or C-peptide AUC change from baseline were observed. The results of other relevant clinical trials and studies of gastrointestinal sweet taste receptors are compared to these findings. The collective evidence supports that sucralose has no effect on glycemic control.
Introduction
Throughout development of sucralose as a sweetener, more than 100 studies were conducted to assess its impact on physiology and general safety, including its potential to affect glycemic control (US HHS FDA, 1988) . They include studies investigating possible effects on carbohydrate metabolism, uptake and storage, chronic studies in model animal species, and human tolerance studies in both normoglycemic and hyperglycemic volunteers (US HHS FDA, 1988; Grotz and Munro, 2009) . Review of these studies led to regulatory confirmation of sucralose safety, including for persons with diabetes (US HHS FDA, 1988; US HHS FDA, 1999; Joint FAO/ WHO, 1989; Health Canada, 2016; FSANZ, 2013; Grotz and Munro, 2009 ). The European Food Safety Authority (EFSA) also permits the following health claim for reduced calorie foods in which caloric reduction is achieved by replacement of nutritive sweeteners with certain non-nutritive sweeteners (NNSs), including sucralose: "Consumption of foods containing low calorie sweeteners instead of sugar induces a lower blood glucose rise after their consumption compared to sugar-containing foods" (EFSA, 2011a) .
At the time of the FDA regulation permitting sucralose use as a sweetener, it was standard to publish just those studies considered core to the regulatory determinations on safety. These studies are reported in the scientific literature (e.g., Food Chem Toxicol, 2000; 38:Suppl 2; Grotz et al., 2003) . FDA also permits access to the full range of studies reviewed through Freedom of Information requests. The study reported herein was not a core study in the safety research, although submitted to and reviewed by FDA and other regulatory agencies around the world (US HHS FDA, 1988; US HHS FDA, 1999; Grotz and Munro, 2009; McNeil Nutritionals, 1996) . This study has significance, however, with the relatively recent discovery of gut sweet taste receptors which has led to new questions about the potential for sucralose to affect blood glucose control. While in vivo studies in humans and animals have largely not supported an effect , studies in humans are largely cross-over studies with only a single sucralose exposure. The study reported and discussed herein is a randomized controlled trial that investigated the effect of sucralose consumption three times per day for 12 weeks on glucose homeostasis in normal healthy volunteers. The study evaluated key measures in glucose and insulin homeostasis, including HbA1c and both fasting and post-prandial glucose, insulin, and C-peptide.
Subjects and methods
The study was conducted at Leicester Clinical Research Centre Ltd (LCRC, Leicester, UK) from August 1995 through February 1996 in accordance with the Declaration of Helsinki and guidelines of the International Conference on Harmonization-Good Clinical Practice and local (UK) laws on human clinical research. Protocol and informed consent form were reviewed and approved by LCRC Independent Ethics Committee (Leicester, UK). All volunteers were informed of the nature and purpose of the study, gave written informed consent to participate before any screening procedures, and could withdraw from the study at any time. The study was conducted preceding the availability of clinical trials registries. Protocol and study report were submitted to FDA as part of the Sucralose Food Additive Petition 7A3987. The study protocol is summarized herein and is on file at Heartland Food Products Group, Horsham, PA. Quality control and assurance procedures were in place throughout the study and included study monitoring conducted by the study sponsor.
Participants
Volunteers were healthy, normal weight, normoglycemic male volunteers, who did not take medications that could affect carbohydrate metabolism (e.g., thiazide diuretics, glucocorticoids or beta blockers), drugs of abuse or more than 2 units of alcohol (unit ¼ 10 mL pure alcohol) daily, and had no family history of diabetes. Females were excluded to avoid the potential effect of menstruation-related hormonal changes on blood glucose and/or insulin measures, particularly in light of the extended study duration (Barata et al., 2013) . Previous research did not indicate a potential gender difference in the metabolic response to sucralose (Baird et al., 2000) .
Study conduct
The study consisted of 3 phases: 4 week screening, 12 week test, and 4 week follow-up. The screening phase consisted of 4 weekly visits. At screening visit 1, volunteers completed a physical examination, ECG and laboratory safety screening of hematology, blood chemistry, and urinalysis. At screening visits 1e4, blood samples were collected for glucose, insulin, C-peptide, and HbA1C analysis. At screening visits 3 and 4, OGTTs were performed. During the test phase, volunteers were supplied, weekly, with bottles of capsules containing either~333 mg sucralose or placebo (cellulose) and instructed to take with meals 3x/day to mimic common timing for sweetener consumption. The planned daily dose was in excess of expected intakes. Test material was provided by Tate & Lyle Specialty Sweeteners, Reading, Berkshire, UK. Sucralose and placebo capsules were standard gelatin capsules that dissolve readily upon ingestion, opaque and identical in weight, size, and color.
Clinic visits were twice weekly in the morning during phase: once weekly for blood sampling, supervised dosing and compliance checks, and twice weekly for urine sample collection. Urine samples were collected for qualitative (present/absent) sucralose analysis. At the time of the study, products containing sucralose were not sold in the country where the study was conducted, so no interference of sucralose from sources outside the study were expected. Blood samples were collected for glucose, insulin, C-peptide, and HbA1C analysis. OGTTs were performed at weeks 6 and 12. Volunteers returned to the clinic 4 weeks after discharge from test phase (follow-up visit) for an OGTT, physical examination, ECG, and laboratory safety screening of hematology, blood chemistry, and urinalysis.
Volunteers were instructed to fast from 22 h on the evening before blood samples were drawn. For OGTTs, this fasting was under clinic supervision, no alcohol was to be consumed for 24 h before, and smoking or drinking caffeine-containing beverages (e.g., tea, coffee, cola) was not permitted while at the clinic and until completion of the OGTT. Volunteers also provided a urine sample for drugs-of-abuse screen on admission to the clinic, and took their morning capsule under supervision immediately before ingesting 75 g of anhydrous glucose dissolved in 200 mL of water. Blood samples were collected for glucose, insulin, and C-peptide measurement at À10, 30, 60, and 120 min. HbA1c was also assessed at the À10 min time point.
For HbA1c, blood samples were collected into EDTA tubes, centrifuged, and plasma samples were frozen at À70 C immediately. For insulin and C-peptide, blood was collected in serum gel tubes containing aprotinin to stabilize C-peptide prior to analysis. Samples were centrifuged, and serum was aliquoted and frozen immediately at À70 C. For glucose, blood samples were collected into fluoride tubes; samples were centrifuged, plasma aliquoted, and immediately frozen at À70 C. Urine samples for sucralose analysis were collected as two 10 mL aliquots and stored at À20 C until analysis.
Samples for analysis of glucose, insulin, C-peptide, and HbA1c were sent to the Diabetes Diagnostic Laboratory, University of Missouri (Columbia, MO, USA). Safety blood tests for hematology and blood chemistry were sent to Huntington Life Sciences Ltd (Huntingdon, Cambridgeshire, UK). Dipstick urinalysis was performed at LCRC. Urine samples were sent to Tate & Lyle Specialty Sweeteners (Reading, Berkshire, UK) for assessment of the presence or absence of sucralose.
Outcomes
Primary outcomes were glucose, insulin, C-peptide, and HbA1c. Additionally, these data were analyzed for change from mean baseline.
Randomization
Volunteers were randomly assigned to treatment groups in a 1:1 ratio according to a computer-generated randomization schedule provided by McNeil Specialty Products Company (Fort Washington, PA, USA). Study treatment capsules were dispensed by an independent pharmacist (Nova-labs, Leicester, UK) following receipt of the randomization schedule. Randomization schedule was known only to the dispensing pharmacist and the McNeil staff who generated the schedule; everyone else was blinded.
Compliance
Compliance was assessed by review of 3 measures: (1) Weekly pill count (# pills missing from weekly bottle/# that should be missing x 100), (2) electronic records of pill bottle usage (each weekly bottle was fitted with a "Track Caps" device [Medical Management System, Aprex Corporation, CA] that automatically recorded dates and times when the bottle was opened; compliance estimated by comparing dates/times bottles were opened to dates and approximate times bottles were expected to be opened), and (3) qualitative assessment of sucralose (presence or absence) in urine samples collected twice weekly (# urine samples positive for sucralose/# urine samples expected to be positive for sucralose x 100).
Statistical analysis
Analyses were performed using SAS version 6.07 (Cary, NC) both mid-study (interim safety analysis) and at study conclusion. Both interim and full study analyses were conducted independently of the sponsor (J. Richard Trout [co-author herein] and Huntingdon Life Sciences, Cambridgeshire, England, respectively).
For each glucose homeostasis parameter, the following procedure was applied. For each volunteer, average baseline (i.e., screening visits 1e4) was calculated and change from this average baseline for the 12 consecutive weeks (test phase) and the followup phase (4 weeks after final dose) was analyzed. A one-way analysis of variance (ANOVA), using treatment as a factor, was carried out at each time point to compare treatment groups. A repeated measures ANOVA was performed on change from baseline data of test phase visits 1e12 with factors treatment, volunteer, week, and interaction of treatment and week. For each treatment and each time point, a Student's t-test analyzed change from average baseline. Validity of ANOVA was assessed by residual plots and Shapiro-Wilk test for normality. The analysis plan shown above followed the analyses specified by the protocol. Intent of the repeated measures ANOVA was to assess overall treatment group difference and consistency of treatment group comparison over post-baseline time points. The one-way ANOVA was used only to compare treatment groups at each time point.
For each OGTT, the following procedure was applied. For each volunteer, average baseline AUC (i.e., screening OGTT visits 3 and 4) was calculated and change from this average baseline AUC for test and follow-up phase visits was analyzed. A one-way ANOVA, using treatment as a factor, was carried out for each time point to compare treatment groups. A repeated measures ANOVA was performed on change from baseline data of test phase visits, with factors treatment, volunteers, time, and interaction of treatment time. For each treatment and each time point, a Student's t-test analyzed change from average baseline. Validity of the analyses was assessed by residual plots and Shapiro-Wilk test for normality. The analysis plan shown above followed the analyses specified by the protocol. Intent of the repeated measures ANOVA was to assess overall treatment group difference and consistency of treatment group comparison over post-baseline time points. The one-way ANOVA was used only to compare treatment groups at each time point.
Sample size was determined so the analysis would have at least 90% power to detect a 50% difference between treatment groups at the 0.05 significance level in fasting C-peptide and fasting insulin.
Safety analyses included all volunteers randomized and exposed to at least 1 dose of study drug.
Equivalence analysis
Additional analyses addressing comparability of sucralose and placebo were performed for fasting glucose, fasting insulin, fasting C-peptide, and HbA1c. For these analyses, 95% one-sided t-intervals were constructed rather than 90% in order to employ a more conservative approach. Similarly, additional analyses were conducted to determine actual magnitude of treatment difference detectable with 80% power using the 0.05 level of significance for fasting glucose, fasting insulin, fasting C-peptide, and HbA1c.
Results

Participants
Forty-eight volunteers were recruited, completed the 4 week/4 visit screening phase, qualified to participate, and began the 12 week test phase 7e14 days after their last screening visit. Three volunteers from the sucralose group withdrew during the test phase for personal reasons; two of these volunteers were replaced and received study treatment according to the predetermined randomization schedule. Forty-six volunteers completed the test phase until Week 6 and attended the OGTT in Week 7. One volunteer did not return to the clinic after Week 6 and after repeated attempts to contact this subject was considered lost to follow up. Forty-seven volunteers, 24 sucralose and 23 placebo volunteers, completed the follow up phase (Fig. 1) .
Mean age, body weight, BMI and race distribution was similar in the sucralose and placebo groups. The majority of volunteers were White. Among all volunteers, there was no significant history of drug or alcohol use or of any chronic medication. Physical exam, blood pressure, pulse, respiratory rate, and 12 lead ECG data collected at screening visit 1 showed no abnormal findings. All laboratory screening values for glucose, insulin, C-peptide, and HbA1c, blood chemistry, and hematology were normal (Table 1) .
The achieved mean daily intake of sucralose was 13.2 mg/kg/day based on the daily sucralose dose (1000 mg/day) and volunteer body weight.
HbA1c, fasting glucose, C-peptide and insulin
No statistically significant differences between sucralose and placebo groups in mean baseline HbA1c, fasting glucose, C-peptide, or insulin at any test visit (visits 1e12) or at follow up visit were observed. Likewise, there were no statistically significant differences between sucralose and placebo groups in mean HbA1c, fasting glucose, C-peptide, or insulin change from baseline ( Fig. 2A-D) . For sucralose and placebo groups, respectively, mean change from baseline over the entire test phase was 0.007% ± 0.023% and 0.028% ± 0.021% for HbA1c; 0.246 ± 0.037 mmol/L and 0.153 mmol/ L ± 0.034 mmol/L for fasting glucose; 0.035 ± 0.015 pmol/mL and 0.023 ± 0.014 pmol/mL for fasting C-peptide, and 1.03 ± 0.29 mU/mL and 0.48 ± 0.27 mU/mL for fasting insulin. None of the betweengroup differences were statistically significant. Statistically significant differences in within-group changes from baseline were either similar for the 2 treatment groups or of small magnitude.
Glucose, C-peptide and insulin AUC levels following OGTT
Results of OGTTs were similar between and among the 2 treatment groups. For both treatment groups, and at all visits during which OGTTs were conducted, mean peak levels were reached within 30, 60, and 30 min for glucose, C-peptide and insulin, respectively, with 2 exceptions. For the sucralose group, mean peak C-peptide level was achieved by 30 min at follow-up and mean peak insulin level was achieved by 60 min at week 6. All glucose, Cpeptide, and insulin levels declined after peak levels were reached. For glucose, levels declined to basal levels or lower (Fig. 3A-C ).
There were no statistically significant differences between the sucralose and placebo groups in mean glucose, insulin or C-peptide AUC at baseline or in mean AUC change from baseline at test visits week 6 or 12 or at follow-up for glucose, insulin or C-peptide (Table 2) .
For sucralose and placebo groups, respectively, mean AUC change from baseline over the entire test phase was 0.237 ± 0.374 mmol/L.h and À0.054 ± 0.366 mmol/L.h for glucose; 7.178 ± 5.062 mU/mL.h and 4.012 ± 4.951 mU/mL.h for insulin; and 0.131 ± 0.145 pmol/mL.h and 0.025 ± 0.141 pmol/mL.h for C-peptide (Table 2) . None of the between-group differences were statistically significant. Statistically significant differences in within-group changes from baseline were few and without obvious trends.
Compliance checks
Compliance checks indicated that nearly all volunteers were 100% compliant throughout by reference to capsule counts and Track Cap system. One volunteer was 66% compliant during week 1 and one was 62% compliant during week 9 of the test phase.
Sucralose was detected in >99% of urine samples (samples taken twice weekly) from volunteers assigned to the sucralose treatment group. No sucralose was detected in urine samples from volunteers assigned to the placebo treatment group.
Equivalence analysis
Analyses of fasting glucose, fasting insulin, fasting C-peptide, and HbA1c in sucralose and placebo groups showed that 95% intervals for each variable met the usual test of 80%e120%. Similarly, results of analyses determining actual magnitude of treatment difference detectable with 80% power using the 0.05 level of significance for fasting glucose, fasting insulin, fasting C-peptide, and HbA1c showed each variable had sufficient sensitivity to detect differences that were <20%. This analysis confirms similar fasting glucose, fasting insulin, fasting C-peptide, and HbA1c responses observed for volunteers receiving sucralose or placebo.
Safety data
Safety assessments, including physical exam, hematology, clinical chemistry, urinalysis, and other safety measures revealed no clinically meaningful differences. Number of volunteers and frequency of occurrence of adverse events (AEs) reported was similar between sucralose and placebo groups. Most AEs were minor in nature and duration. All were self-limiting and resolved without sequelae. No AE was considered definitely related to treatment. A single serious AE was reported, an episode of tonsillitis in a volunteer receiving sucralose, which required a 48-hour hospital admission for treatment with intravenous antibiotics. The relationship to sucralose was classified as remote. At the post study visit e 4 weeks after final capsule administration e all volunteers were considered well. One volunteer had an abnormal ECG, however, subsequent follow-up by a cardiologist diagnosed longstanding intermittent, asymptomatic supraventricular tachycardia and found the abnormal ECG unrelated to participation in the study and previously unnoticed. The volunteer had no other signs/ symptoms and took, and was put on, no medications.
Discussion
The past decade has marked significant interest in the ability of NNSs, including sucralose, to have an adverse effect on blood glucose control. Interest stemmed largely from studies investigating potential effects of NNSs on gut sweet taste receptors. In isolated cells or tissues, several types of sweeteners, including sucralose, were shown to activate gut sweet taste cell receptors with an accompanying increased rate of glucose absorption by intestinal enteroendocrine cells (Mace et al., 2007; Margolskee et al., 2007) . Depending on testing conditions, this change was considered to be mediated by an effect on either active glucose transport, via sodium-dependent glucose transport protein (SGLT1) (Margolskee et al., 2007) , or diffusive glucose transport, via apical glucose transporter type 2 (GLUT2) pathway (Mace et al., 2007) . Some, but not all studies of intestinal enteroendocrine cells incubated with medium containing sucralose, or other NNSs, also showed increased secretion of GLP-1 and GIP (Margolskee et al., 2007; Jang et al., 2007; Ohtsu et al., 2014) , gut hormones known to have a role in overall glucose control. Early research showed that saccharin, cyclamate, stevioside and acesulfame-K (ace-K) can all augment insulin release from isolated rat pancreatic islet cells incubated in the presence of glucose (Malaisse et al., 1998) . More recently, studies in MIN6 cells (mouse pancreatic insulinoma cell line) showed augmented glucose uptake and insulin secretion when incubated with high concentrations of sucralose (10e50 mM), or other NNSs, depending on glucose concentration of the cell incubation medium (Nakagawa et al., 2009; Nakagawa et al., 2013) . Finally, two studies, a clinical trial by Pepino and associates (Pepino et al., 2013 ) and a study in mice by Suez et al. (2015) reported an increase in blood glucose levels following exposure to sucralose. From these studies, it has been hypothesized that sucralose, and other NNSs, can adversely affect blood glucose regulation, e.g., by affecting total insulin secretion, glucose uptake and/or glucose utilization either by direct effect or via effects on GLP-1 or GIP.
To date, the role of sweet taste receptors in glucose control is not clear (Young, 2011) . Testing methodologies and other factors may limit reliability of extrapolating results of studies discussed above to overall effects on blood glucose control. Importantly, since the early studies of NNSs showing that they activate non-gustatory sweet taste receptors, much additional research has been conducted to clarify the potential for sucralose to affect blood glucose control in humans. Table 3 provides a list of clinical trials investigating effect of sucralose on blood glucose, insulin and/or C-peptide. With exception of the Pepino et al. (2013) study, studies show no effect of sucralose on glycemic control.
The Pepino study was a non-blinded, randomized, cross-over study in morbidly-obese, pre-diabetic, NNS-naïve volunteers who were primarily women of menstruating age. Blood glucose and insulin levels were determined after treatment with either 60 ml plain water or sucralose (2 mmol/L) given immediately before a 75 g OGTT. No change in total blood glucose AUC was reported; mean peak blood glucose AUC, while reported to be increased, was within the normal range (ADA, 2010). Statistically significant increases in measures of insulin response reflect small mean differences. A clinically meaningful effect on insulin is not expected in absence of an effect on glucose AUC. Differences reported may reflect natural intra-individual differences in glycemic response to an OGTT, particularly within this group of morbidly obese subjects whose glycemic response to the control OGTT indicates an impaired glucose tolerance.
While findings of the Pepino study are contrasted by numerous other clinical trials, including studies in overweight and obese subjects, the majority of these are cross-over studies with only a single exposure to sucralose. Longer-term studies help address whether repeated consumption of sucralose would be likely to affect blood glucose control.
The study reported herein, a 12-week, double-blind, parallelgroup study, adds to the collective evidence that sucralose is without effect on blood glucose control. All glucose, insulin, Cpeptide, and HbA1c levels measured throughout the study were within normal range. There were no statistically significant differences between sucralose and placebo groups in changes from baseline for fasting glucose, insulin, C-peptide, or HbA1c. No clinically meaningful differences were noted in time to peak levels or return towards basal levels in OGTTs. No statistically significant difference between sucralose and placebo in mean glucose, insulin, or C-peptide AUC change from baseline were observed. The findings are supported by absence of any obvious study confounders. Furthermore, an equivalence analysis designed to detect differences that were <20% with at least 80% power confirmed similar fasting glucose, fasting insulin, fasting C-peptide, and HbA1c responses for volunteers receiving sucralose or placebo. Additionally, the inclusion of repeated OGTTs during baseline allows for increased confidence in assessment of changes from (average) baseline.
There are certain limitations to this study with regard to extrapolation of the results. As a primarily out-patient study, test material intake was largely outside the supervision of investigators or clinic staff, however the design included measures to support compliance. All three compliance measures, weekly pill counts, erecords of capsule bottle openings, and evaluation of urine for the presence of sucralose, also indicated that volunteers were highly compliant. At the time of the study, food products with sucralose
were not yet approved for use in Europe, so chance ingestion of sucralose was unlikely. While between-group differences in lifestyle were also possible, the study design allowed sucralose to be consumed with normal daily eating habits; studies have shown that a requirement to record diet and physical activity can impact study outcomes (Robinson et al., 2015) . The study also was conducted in only younger males. This population was chosen, however, since it avoided the potential effect of menstruationrelated hormone changes on glycemic control, as well as the potential of decreased sensitivity to changes in blood glucose levels that can occur with an older population. The daily sucralose intake was greater than actual expected intakes (US HHS FDA, 1999), but this was an intentional outcome to allow investigation of possible effect with even extremes of use. Based on the average sweetening potency of sucralose (about 600X sweeter than sugar) (Wiet and Beyts, 1992) , sucralose intake of~333mg/meal is equivalent to an intake of~200 g sugar/meal, roughly the amount of sugar ingested from five 12-ounce cans of non-diet (full-sugar) cola-flavored soda or 3 cans and 2 to 3 candy bars.
Evidence from clinical trials conducted since the FDA approval of sucralose significantly adds to the conclusion that sucralose is without effect on glycemic control (Pepino et al., 2013; Brown et al., 2009; Temizkan et al., 2015; Mezitis et al., 1996; Wu et al., 2012; Brown et al., 2011; Stellingwerff et al., 2013.; Ford et al., 2011; Boyle et al., 2016; Ma et al., 2010; Ma et al., 2009; Steinert et al., 2011; Peters et al., 2016) . These studies show no ability of sucralose to elicit a cephalic phase insulin response (Ford , 2011) . There is basically a flat-line glucose and insulin response relative to fasting baseline, or a response not different from water, with acute sucralose exposure in the absence of carbohydrate (Stellingwerff et al., 2013; Ma et al., 2009; Ma et al., 2010; Ford et al., 2011; Boyle et al., 2016; Steinert et al., 2011) . The study reported here also shows no changes in weekly fasted glucose or insulin levels over the 12 weeks. There is no evidence of increased blood glucose absorption in studies where sucralose was directly delivered to stomach or small intestine, in presence or absence of bolus carbohydrate load (Ma et al., 2010; Steinert et al., 2011) , or in a recent study where various doses of sucralose were given orally preceding an OGTT (Sylvetsky et al., 2016) . In a study specifically designed to explore the potential of NNSs to increase carbohydrate delivery and oxidation (Steinert et al., 2011) , sucralose had no effect, "which suggests no significant change to carbohydrate transporter function or density." There was also no effect on plasma glucose, insulin, or lactate concentrations or cardiovascular and metabolic responses that are relevant to assessment of glucose- mobilization for energy production. Similarly, in subjects consuming a low-calorie sports drink sweetened with nutritive or primarily non-nutritive sweeteners (ace-K and sucralose), blood glucose levels following exercise were significantly lower than baseline in subjects receiving the low-calorie drink. This finding further supports no effect of increased glucose absorption following exposure to either of these sweeteners (Peltier et al., 2011) . In general, studies also indicate no effect based on gender, age range, body weight, or baseline glycemia (with and without diabetes, either type 1 or type 2) ( Table 3 ). This lack of effect is also seen across a range of sucralose intakes and study conditions, including in the absence or presence of carbohydrate intake. Suez et al. (2014) . asserted that sucralose will adversely affect blood glucose, mediated by an effect on the gut microbiota, based on studies of various NNS in mice and a single investigation in humans. The latter study investigated effects of saccharin and not sucralose. In this week-long study, they found 4 participants had higher and 3 participants had lower blood glucose AUCs following a standard OGTT, results which the investigators interpreted as "responders" and "non-responders", respectively. Such results could easily be considered a demonstration of no effect, and reported changes in the gut microbiota profiles are not corroborated as ones that will lead to perturbations in blood glucose control (Mandal et al., 2015) . In the single study that included investigation of sucralose, mice drank water for 11 weeks that contained either no sweetener or a blend of a NNS (sucralose or other NNS) and carbohydrate, and, for an additional 4 weeks, drank the same sweetened or unsweetened water that now included a fixed dose of antibiotics. OGTTs were conducted at 11 weeks and at the end of the study. There was no control for potential differences in carbohydrate intake and no baseline OGTT results were reported for comparison. Blood glucose AUC was reported as increased at 11 weeks for mice receiving the NNS/carbohydrate blends (mean of all blends combined vs. "control"), but not at the conclusion of the study. Based on this, Suez et al. conjectured that NNSs, including sucralose, caused an adverse effect on glucose control by altering the gut microflora profile, because the same type of differences were not found when mice were treated with antibiotics. However, absence of an effect on blood glucose AUC in mice treated with antibiotics is not evidence that NNSs caused either an effect on gut microflora or the observed between-group difference in post-OGTT response. Furthermore, metabolic data shows no evidence of sucralose being a substrate for gut microflora, as sucralose is not broken down in the gastrointestinal system (Grotz and Munro, 2009; Sims et al., 2000) and an increase in post-prandial glucose is not indicated by other rodent studies. No effects on blood glucose were found in healthy, normal rats consuming sucralose-treated feed every day throughout the lifespan (Mann et al., 2000) , or receiving sucralose by gavage in the absence or presence of an intraperitoneal OGTT (Fujita et al., 2009 ). Effects were also not found in Zucker diabetic fatty rats (Fujita et al., 2009) , and in streptozotocin-induced diabetic Sprague Dawley rats exposed to a commercially available sucralose/carbohydrate blend, blood glucose concentrations were decreased, and insulin levels were unchanged. (Saada et al., 2013) .
As far as the potential for sucralose to affect blood glucose control by alteration of gut hormonal responses, most clinical trials do not show clinically meaningful effects of sucralose on circulating incretin levels. No effect is seen on GIP, PYY, or ghrelin (Pepino et al., 2013; Brown et al., 2009; Wu et al., 2012; Brown et al., 2011; Ford et al., 2011; Ma et al., 2009; Steinert et al., 2011; Sylvetsky et al., 2016) . GLP-1 is reported to be increased in a few studies in healthy overweight and obese adults (Brown et al., 2009; Temizkan et al., 2015) and in a study in healthy normal-weight youths with or without type 1 diabetes . However, in three of the latter studies (Brown et al., 2009; Sylvetsky et al., 2016) , sucralose was in a commercial carbonated soft-drink containing other ingredients, and, when the same amount of sucralose was given in plain seltzer, no increase in GLP-1 was found. Additionally, no increase in GLP-1 is reported in studies of morbidly obese adults (Pepino et al., 2013) , healthy overweight or normal weight adults (Wu et al., 2012; Wu et al., 2013; Ford et al., 2011; Ma et al., 2010; Steinert et al., 2011; Sylvetsky et al., 2016) , or in overweight youths or adults with type 2 diabetes Temizkan, 2015) . A recent study in human enteroendocrine NCI-H716 cells, using a liquid chromatography-tandem mass spectrometry methodology developed to enable quantification at picomolar quantities, also found no increase in GLP-1 secretion with exposure of cells to sucralose; while exposure to positive controls, including glucose, showed a clear increase (Amao et al., 2015) . Increases in GLP-1 seen in a few clinical studies may also be related to intra-individual variation, especially since these studies each employed a single-dose cross-over design. More importantly, in none of these studies was there a report of a statistically significant effect on blood glucose levels.
A recent review paper also found lack of evidence for an effect of NNSs on human gut function and that studies of NNSs "consistently fail to replicate any of the effects on gastric motility, gut hormones, or appetitive responses evoked by caloric sugars" (Bryant and Mclaughlin, 2016) . Similarly, a review of studies of gastrointestinal sensing via sweet taste pathways ("intestinal cell types equipped with sweet taste transduction molecules") reports that, "Despite evidence supporting an intestinal role of artificial sweeteners in cell systems and a number of animal studies, some studies now suggest that [artificial] sweeteners may be functionally inert in the intestine" (Young, 2011) . Other research is suggesting similar conclusions (e.g., Sclafani et al., 2010; Sclafani and Ackroff, 2012; Chaudhry et al., 2013) .
In short, full comprehension of controls of glycemia with (Young, 2011; Bryant and Mclaughlin, 2016) . Uncertainty exists with regard to the contribution of sweet taste cell signaling in the human intestine in triggering of gut hormone release and neuronal responses involved in nutrient sensing by the brain. Sensory studies in sweet-taste receptor knock-out (KO) mice indicate that sensing sugar, a physiologic process that starts at the gastrointestinal level, does not require sweet taste transduction (de Araujo et al., 2008) . Rats do not alter behavior towards sweetness with the intraduodenal presence of sucralose (Schier et al., 2012) . Mice without sweet taste receptors also develop a preference for water with sucrose but not for water with sucralose. Moreover, blood glucose response to intake of sucrose is virtually the same between wild-type and sweet taste receptor KO mice, indicating that activation of sweet taste receptor is not a determinant in glucose absorption from the gastrointestinal tract. Similarly, food intake and body weight are unaffected in T1R3 KO mice vs. wild type mice, also suggesting that sweet taste perception is not a major determinant in absorption of glucose from carbohydrate in food (Treesukosol et al., 2011) . Sensory studies in mice also indicate that sucralose does not drive sugar intake by turning on sweet taste receptors (Sclafani et al., 2010) . Importantly, early research indicating a potential role of sucralose on glycemic control via non-gustatory sweet taste receptor activation is largely sourced from studies utilizing isolated cell and tissue systems, which might respond differently in the intact physiologic system. Responses of these cells/tissues might be impacted by other intercellular signals and physiologic controls in the regulation of glucose homeostasis. Responses may also have to do with effects of the testing system, e.g., potential osmotic effects with use of perfusion solutions with very high NNS concentration, or ambient glucose levels that may pre-dispose cells to transient increased sweet taste receptor responsiveness. Further, outcomes observed may be transient or insufficient to cause a clinically meaningful effect.
In sum, the double-blind randomized trial in normoglycemic volunteers reported herein found no effect of sucralose, consumed in amounts well above expected daily intakes for 12 weeks, on standard measures of glucose homeostasis. The findings are also consistent with a multi-center 3-month study in persons with type 2 diabetes that found no effect on HbA1c, a measure of long-term glycemic control and numerous shorter-term RCTs showing no effect of sucralose on blood glucose control. This study thus contributes to the collective evidence that sucralose would not adversely affect blood glucose control with repeated daily consumption.
Conclusion
This 12-week, double-blind, parallel-group study corroborates collective evidence that daily consumption of sucralose is without effect on blood glucose control. All glucose, insulin, C-peptide, and HbA1c levels measured throughout the study were within normal range. There were no statistically significant differences between sucralose and placebo groups in changes from baseline for fasting glucose, insulin, C-peptide, and HbA1c. No clinically meaningful differences were found between groups in glucose, insulin or Cpeptide responses to OGTTs. The results are consistent with the fact that sucralose contributes no calories to the diet. While the discovery of non-gustatory, T1R family of sweet taste receptors has been a significant tool in research investigating the pathways of nutrient-sensing and potential role of sweet taste receptors therein, numerous studies in humans, including the study reported here, and more recent studies in animals provide strong evidence that sweet taste signal transduction as a result of sucralose consumption does not lead to clinically meaningful effects on blood glucose. This information is valuable to both health care professionals and the general public in considering the potential benefits of using sucralose, or other FDA-approved NNSs, as a means to reduce sugar intake, a dietary change that is currently advocated by several prominent health and nutrition authorities (WHO, 2015; AHA).
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